SCHEMBL4924813

SCHEMBL4924813

CCOC(=O)c1ccc(NC(=O)Nc2ccc(C(=O)OCC)c(Cl)c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.69
MAPT P10636 8/20 0.63
MEN1 O00255 6/20 0.63
KMT2A Q03164 6/20 0.63
GAA P10253 1/20 0.63
CASP3 P42574 2/20 0.63
SENP7 Q9BQF6 2/20 0.63
USP2 O75604 1/20 0.59
LMNA P02545 1/20 0.59
MAPK1 P28482 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.57
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
TSHR P16473 1/20 0.53
NAMPT P43490 1/20 0.53
ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4915834 0.88 KMT2A (0.65) TRPV1MAPTMEN1KMT2AGAA
SCHEMBL4922490 0.86 MAPT (0.76) TRPV1MAPTMEN1KMT2AGAA
SCHEMBL5176197 0.85 MEN1 (0.55) TRPV1MAPTMEN1KMT2AGAA
SCHEMBL4111911 0.83 TRPV1 (0.75) TRPV1MAPTMEN1KMT2AGAA
SCHEMBL4919753 0.83 MAPT (0.81) TRPV1MAPTMEN1KMT2AGAA
SCHEMBL5175447 0.82 MAPT (0.70) TRPV1MAPTMEN1KMT2AGAA
SCHEMBL4104609 0.82 TRPV1 (1.00) TRPV1MAPTMEN1KMT2AGAA
SCHEMBL1760466 0.81 CA12 (0.57) LMNACA12CA1CA2CA9
SCHEMBL27783039 0.80 KMT2A (0.50) KMT2ACA12CA1CA2CA9
SCHEMBL8856886 0.80 KMT2A (0.50) KMT2ACA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP claimed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R TRPV1 446/4885MAPT 4151/4885MEN1 4843/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R TRPV1 446/4885MAPT 4151/4885MEN1 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.